2713-62-4 Usage
General Description
2-(Hexafluoro-2-hydroxyisopropyl)aniline is a chemical compound with the molecular formula C9H5F6NO. It is a derivative of aniline, featuring a hexafluoroisopropyl group attached to the amine nitrogen. 2-(HEXAFLUORO-2-HYDROXYISOPROPYL)ANILINE is a colorless liquid that is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals, as well as for specialty applications in various industries. It is known for its high stability and resistance to oxidation and reduction, making it a valuable building block for the creation of new chemical compounds. Additionally, its strong electron-withdrawing properties make it useful in certain organic reactions. However, it is important to handle this compound with care, as it can be toxic when inhaled or ingested, and it may also cause skin and eye irritation.
Check Digit Verification of cas no
The CAS Registry Mumber 2713-62-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,7,1 and 3 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 2713-62:
(6*2)+(5*7)+(4*1)+(3*3)+(2*6)+(1*2)=74
74 % 10 = 4
So 2713-62-4 is a valid CAS Registry Number.
2713-62-4Relevant articles and documents
Synthesis and inhibitory activity on hepatitis C virus RNA replication of 4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-2-propyl)aniline analogs
Matsuno, Kenji,Ueda, Youki,Fukuda, Miwa,Onoda, Kenji,Waki, Minoru,Ikeda, Masanori,Kato, Nobuyuki,Miyachi, Hiroyuki
, p. 4276 - 4280 (2014/09/17)
Using our recently developed assay system for full-genome-length hepatitis C virus (HCV) RNA replication in human hepatoma-derived Li23 cells (ORL8), we identified 4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-2-propyl)aniline analog 1a as a novel HCV inhibitor. St
Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders
-
, (2008/06/13)
The present invention provides methods of treating skin disorders includes delivering to a mammal a composition containing a compound of formula I, or tautomers thereof, in a regimen, wherein formula I is: and wherein R1-R5 and Qsup
